Introduction
============

Overweight and obesity are defined as abnormal or excessive fat accumulation that may impair health[@b1-vhrm-13-001] and have been reported to be associated with glucose in tolerance, dyslipidemia, and hypertension, thus increasing cardiovascular risks.[@b2-vhrm-13-001],[@b3-vhrm-13-001] Furthermore, cardiovascular disease (CVD) is the leading cause of death worldwide.[@b4-vhrm-13-001] On the other hand, underweight is also associated with increased all-cause mortality compared to normal weight after adjustment for covariates.[@b5-vhrm-13-001]--[@b8-vhrm-13-001] It is an obvious fact that body fat distribution influences morbidity and mortality. Thus, healthy ranges for percentage body fat (%BF) should be considered in the management of intensive therapeutic approaches for obesity.[@b9-vhrm-13-001]--[@b11-vhrm-13-001] The most commonly used surrogate marker of %BF is body mass index (BMI), which is calculated from a person's height and weight. BMI is reliable and provides a fair indication of body fat level but is not a perfect system for measuring body fat.[@b12-vhrm-13-001]--[@b14-vhrm-13-001] A BMI \<18.5 kg/m^2^ is defined as underweight and a BMI \>25 kg/m^2^ as overweight. Actually, numerous studies have documented a U- or J-shaped association between BMI and mortality and an association of increased mortality rate with relatively low or high BMI.[@b15-vhrm-13-001],[@b16-vhrm-13-001] In Japan, the ideal body weight that is associated with the lowest mortality corresponds to a BMI of 22 kg/m^2^ in both men and women.[@b17-vhrm-13-001] Arterial stiffness is a significant surrogate marker of subclinical atherosclerosis, and increased arterial stiffness is independently associated with an increased risk of major adverse cardiovascular events (MACEs).[@b18-vhrm-13-001],[@b19-vhrm-13-001]

Recently, a novel arterial stiffness diagnostic parameter called cardioankle vascular index (CAVI) has been developed in Japan, which allows quantification of the stiffness parameter beta independent of blood pressure (BP).[@b20-vhrm-13-001]--[@b22-vhrm-13-001] This stiffness parameter has adequate reproducibility for clinical use[@b23-vhrm-13-001]--[@b27-vhrm-13-001] and is associated with a number of risk factors and severity of CVD.[@b28-vhrm-13-001]--[@b33-vhrm-13-001] CAVI has also been reported to be an independent predictor of MACE.[@b34-vhrm-13-001],[@b35-vhrm-13-001] Moreover, an increase in the number of risk factors for metabolic syndrome correlates positively with increased CAVI, probably due to insulin resistance.[@b36-vhrm-13-001] Weight gain most likely contributes to the risk of increase in arterial stiffness. Nevertheless, the relationship between BMI and arterial stiffness has not been fully elucidated.

The aim of this cross-sectional study was to investigate whether BMI is associated independently with arterial stiffness assessed by CAVI after adjustment for covariates in healthy Japanese subjects. Additionally, gender difference in the relationship between BMI and CAVI was also examined.

Subjects and methods
====================

Design
------

This retrospective cross-sectional study was approved by the Institutional Review Board and Ethics Committee of Sakura Hospital, School of Medicine, Toho University (no S16002). Written informed consent was obtained from the participants.

Data collection and laboratory assay methods
--------------------------------------------

A total of 23,257 Japanese urban residents (12,729 men and 10,528 women) residing in major cities nationwide, who participated in the CVD and cancer screening program provided by the Japan Health Promotion Foundation between 2004 and 2006, were studied. Subjects were excluded if they were taking any medication or had a past history of heart disease, hypertension, stroke, diabetes, nephritis, or gout. Height and body weight were measured, and BMI was calculated \[weight (kg) divided by square of height (m^2^)\]. Obesity was defined as BMI ≥25 kg/m^2^, which is the definition for obesity in adult Japanese population according to the Examination Committee of Criteria for Obesity Disease in Japan.[@b37-vhrm-13-001] Blood was collected from the antecubital vein in the morning after 12-hour fasting to determine γ-glutamyl transpeptidase (γ-GTP), fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), total cholesterol (TC), triglycerides (TGs), high-density lipoprotein-cholesterol (HDL-C), creatinine, and uric acid. All the blood levels were measured according to standard procedures. Non-HDL-C was defined as the difference between total and HDL-cholesterol. HbA1c (%) measured by the Japan Diabetes Society (JDC) method was converted to NGSP value (%) using the following formula: HbA1c (NGSP) (%) = HbA1c (JDS) (%) + 0.4%.[@b38-vhrm-13-001] Impaired fasting glucose (IFG) was defined as fasting glucose levels of 100 to 125 mg/dL.[@b39-vhrm-13-001]

Measurement of CAVI and BP
--------------------------

CAVI was measured using a VaSera VS-1000 (Fukuda Denshi Co Ltd, Tokyo, Japan) by the methods described previously.[@b20-vhrm-13-001] Cuffs were applied to bilateral upper arms and ankles, with the subject lying supine and the head held in midline position. After resting for 10 minutes, the examinations were performed. To detect the brachial and ankle pulse waves with cuffs, a low cuff pressure from 30 to 50 mmHg was used to ensure minimal effect of cuff pressure on hemodynamics. Furthermore, BP was measured thereafter. Hypertension was defined as systolic BP (sBP) ≥140 mmHg and/or diastolic BP (dBP) ≥90 mmHg.[@b40-vhrm-13-001] Finally, for the convenience of comparison with the pulse wave velocity (PWV), scale conversion was performed. CAVI was calculated by the following formula: CAVI = *a*{(2*r*/∆*P*) × ln(*P*s/*P*d)PWV2} + *b*, where *P*s is sBP, *P*d is dBP, ∆*P* is *P*s − *P*d, *r* is blood density, and *a* and *b* are constants. BP was measured from the cuff of the upper arm. PWV was obtained by dividing the vascular length by the time for which the pulse wave propagated from the aortic valve to the ankle and was measured using cuffs at the upper arms and ankles. All the measurements and calculations were performed automatically by the VaSera. Subjects with ankle--brachial indices \<0.90 were excluded, because patients with severe arterial occlusive diseases may give falsely low CAVI.[@b20-vhrm-13-001] The mean coefficient of variation of CAVI measured by this method is \<5%, which is sufficiently small for clinical usage and indicates that CAVI has good reproducibility.[@b25-vhrm-13-001]

Statistical analysis
--------------------

All data are expressed as mean ± standard deviation. The SPSS software (version 11.5; SPSS Inc, Chicago, IL, USA) was used for statistical processing. Student's *t*-test was performed to examine gender difference in clinical variables. The relationship between CAVI and clinical variables was analyzed using multiple regression analysis. The relationship of CAVI with BMI was analyzed using analysis of variance (ANOVA) after adjusting for confounders of CAVI, together with trend analysis. Logistic regression analysis was used to identify contributors of high CAVI (≥90th percentile) and expressed as odds ratio (OR) with 95% confidence interval (CI). In all comparisons, *P* values \<0.05 were considered statistically significant.

Results
=======

Characteristics of male and female participants
-----------------------------------------------

In this study, a total of 23,257 Japanese urban residents (12,729 men and 10,528 women) aged from 20 to 74 (mean 47.1 ± 12.5) years were screened. [Table 1](#t1-vhrm-13-001){ref-type="table"} compares the clinical characteristics of male and female participants. Compared with women, men had significantly and markedly higher BMI (23.9 ± 3.2 vs. 21.7 ± 3.3 kg/m^2^, *P* = 0.003) and CAVI (7.96 ± 1.14 vs. 7.69 ± 0.97, *P* \< 0.001).

Prevalence of major cardiovascular risk factors
-----------------------------------------------

The prevalence of traditional cardiovascular risks in participants is shown in [Table 2](#t2-vhrm-13-001){ref-type="table"}. The proportions of older age, obesity, and hypertension were significantly (*P* \< 0.001) higher in men than in women, whereas the proportions of IFG and low HDL-cholesterol (defined as HDL-C \<40 mg/dL) were not significantly different ([Table 2](#t2-vhrm-13-001){ref-type="table"}).

Correlation of CAVI with clinical variables analyzed by multiple regression model
---------------------------------------------------------------------------------

Next, we examined the factors associated with CAVI. [Table 3](#t3-vhrm-13-001){ref-type="table"} summarizes the results of a multiple regression analysis for the correlation between CAVI and clinical variables. TG was also omitted because of intraclass correlation with HDL-C, and non-HDL-C was added instead. Age was a major independent predictor of CAVI (*b* coefficient = 0.584, *P* \< 0.001). Additionally, a low correlation between CAVI and gender (*b* = 0.149, *P* \< 0.001), BMI (*b* = −0.119, *P* \< 0.001), sBP (*b* = 0.139, *P* \< 0.001), or HDL-C (*b* = 0.107, *P* \< 0.001) was observed. These confounders, except gender and BMI, were adjusted in subsequent analyses of CAVI as shown in [Table 4](#t4-vhrm-13-001){ref-type="table"} and [Figure 1](#f1-vhrm-13-001){ref-type="fig"}.

Characteristics of male and female participants stratified by tertiles of BMI
-----------------------------------------------------------------------------

Participants were divided into men and women, and each gender group was stratified by BMI tertiles into the following three groups: lower (T1), middle (T2), and upper tertile (T3). Among 12,729 men, 4,181 were stratified into T1 (BMI ≤22.2 kg/m^2^), 4,365 into T2 (22.3--24.9 kg/m^2^), and 4,183 into T3 (≥25.0 kg/m^2^). Among 10,528 women, 3,585 were stratified into T1 (≤20.0 kg/m^2^), 3,462 into T2 (20.1--22.5 kg/m^2^), and 3,481 into T3 (≥22.6 kg/m^2^). [Table 4](#t4-vhrm-13-001){ref-type="table"} compares their clinical characteristics. CAVI was adjusted for confounders identified in the multiple regression model as shown in [Table 3](#t3-vhrm-13-001){ref-type="table"}. In both genders, sBP, dBP, γ-GTP, FPG, HbA1c, TC, TG, and non-HDL-C increased, while adjusted CAVI and HDL-C decreased progressively with increasing BMI tertile.

ORs (95% CIs) for high CAVI (≥90th percentile)
----------------------------------------------

Furthermore, we examined the factors associated with high CAVI using multivariate logistic regression model with dichotomous variables ([Table 5](#t5-vhrm-13-001){ref-type="table"}). High CAVI was defined as ≥90th percentile of CAVI (9.20 in all participants). Gender and major cardiovascular risks were entered into the model as shown in [Table 2](#t2-vhrm-13-001){ref-type="table"}. The analysis identified the following factors to be independently associated with high CAVI: male gender (OR: 2.26, *P* \< 0.001), older age (OR: 15.6, *P* \< 0.001), hypertension (OR: 2.28, *P* \< 0.001), and IFG (OR: 1.17, *P* = 0.0428). Interestingly, obesity correlated negatively with high CAVI (OR: 0.804, *P* \< 0.001). Low HDL-cholesterol was not a significant independent predictor of high CAVI.

Relationship of adjusted CAVI with BMI in men and women
-------------------------------------------------------

[Figure 1](#f1-vhrm-13-001){ref-type="fig"} shows the relationship of adjusted CAVI with BMI in ([Figure 1A](#f1-vhrm-13-001){ref-type="fig"}) men and ([Figure 1B](#f1-vhrm-13-001){ref-type="fig"}) women. In both genders, a trend test after ANOVA detected an inverse linear relationship (*P* \< 0.001) between adjusted CAVI and BMI throughout the entire BMI distribution.

Discussion
==========

In this cross-sectional study, gender, age, BMI, BP, and HDL-cholesterol were major independent variables associated with CAVI in 23,257 healthy Japanese subjects. After adjusting for confounders, CAVI correlated negatively with BMI in both genders. Furthermore, obesity was identified as an independent negative predictor of high CAVI (≥90th percentile), while male gender, hypertension, and IFG were found to be independent positive predictors. Consequently, the present study is the first report to demonstrate an inverse relationship between CAVI and BMI in healthy middle-aged subjects. Note that most of the participants in the present study were nonobese subjects without metabolic disorders. If the study was conducted in obese subjects with metabolic disorders, the results might have been markedly different.

Weight gain has been associated with vascular remodeling and increased cardiovascular mortality.[@b41-vhrm-13-001] CAVI has been shown to be high in the abdominal obesity/metabolic syndrome and decrease by body weight reduction.[@b42-vhrm-13-001] Insulin resistance, a consequence of weight gain, has been recognized as an independent predictor of vascular stiffening and other elements of diabetic vasculopathy.[@b43-vhrm-13-001] Our finding of an inverse relationship between CAVI and BMI might seem inconsistent with previous reports. However, the interaction of weight gain with insulin resistance in the regulation of vascular pathophysiology involves complex mechanisms that are not fully understood. Thus, the mechanism of vascular adaptation to fat accumulation remains controversial. In fact, a negative association of obesity with vascular stiffening has been reported in children and adolescents[@b44-vhrm-13-001]--[@b46-vhrm-13-001] but not in older adults or the elderly.[@b47-vhrm-13-001]--[@b50-vhrm-13-001] We therefore stratified the participants in this study by age into tertiles: lower (33.1 ± 5.0 years, n = 7,878), middle (47.1 ± 3.8 years, n = 7,577), and upper (61.0 ± 6.1 years, n = 7,802) and investigated the contribution of BMI to CAVI in each group using logistic regression analysis. We found approximately equal degree of inverse relationship between CAVI and BMI in all three tertiles (data not shown). However, these data do not imply a similar inverse relationship between CAVI and BMI in elderly subjects. While weight gain is a risk factor for CVD, an inverse relationship between BMI and CAVI was observed in the present study. An increase in number of risk factors for metabolic syndrome has been shown to correlate positively with an increase in CAVI.[@b36-vhrm-13-001] Furthermore, we observed previously that weight reduction resulted in a decrease of CAVI in 47 obese (BMI: 33.3 ± 7.5 kg/m^2^) Japanese subjects with metabolic disorders.[@b42-vhrm-13-001] In that study, change in visceral fat area alone contributed to the change in CAVI. From the previous findings, we hypothesize that systemic accumulation of adipose tissue per se leads to decreased arterial stiffness in nonobese subjects and in obese subjects without metabolic disorders, and excessive accumulation of visceral fat may induce an increase in arterial stiffness from insulin resistance. However, the mechanism and the threshold of the effect of BMI on change in arterial stiffness are not fully understood. Despite weight gain being a risk of CVD development, an obesity paradox exists in which obese patients with heart failure, hypertension, and chronic renal disease have better prognosis with lower mortality than normal weight individuals.[@b51-vhrm-13-001]--[@b54-vhrm-13-001] For example, \~10--25% of obese individuals are metabolically healthy due to preserved insulin sensitivity.[@b55-vhrm-13-001] The plausible mechanisms for this reverse epidemiology may be explained by greater metabolic reserves, less cachexia, attenuated response to renin--angiotensin--aldosterone system, increased muscular strength, implications related to cardiorespiratory fitness, and others. Furthermore, various protective cytokines and neuroendocrine profiles in obese patients may account for this phenomenon.[@b56-vhrm-13-001]--[@b58-vhrm-13-001] Similarly, adipose tissue-derived cytokines may explain the paradox in arterial stiffness observed in the present study. Shiba et al[@b59-vhrm-13-001] reported that intravitreal injection of antivascular endothelial growth factor (anti-VEGF) drugs decreased CAVI and carotid intima--media thickness, probably due to attenuation of vasa vasorum and improved kidney function. Inhibition of angiogenesis inducers such as VEGF may therefore result in a decrease in arterial stiffness. On the other hand, tenomodulin (TNMD), a putative angiogenesis inhibitor, has been shown to be highly expressed in human adipose tissue, especially in obese subjects.[@b60-vhrm-13-001] Furthermore, a recent study suggests that TNMD acts as a protective factor in visceral adipose tissue to alleviate insulin resistance in obesity.[@b61-vhrm-13-001] We have previously reported that improved insulin resistance may contribute to decreased CAVI in obese[@b42-vhrm-13-001] and type 2 diabetic patients.[@b62-vhrm-13-001]--[@b64-vhrm-13-001] These reports suggest that adipose tissue may affect systemic vascular function through expression of antiangiogenic factors such as TNMD. However, whether the decrease in arterial stiffness through inhibition of angiogenesis provides favorable effects is questionable, because antiangiogenic factor may impair the development of collaterals, which is an important mechanism to compensate for obstructive artery disease.[@b65-vhrm-13-001] Further elucidation of the cause--effect relationship between accumulation of adipose tissue and regulation of arterial pathophysiology is required.

What is the clinical efficacy of our findings? We hypothesized that CAVI might be useful to exclude "malignant obesity", which was rapidly needed to receive intensive medical interventions. Obese subjects with relatively low CAVI may reveal "benign obesity", which means normal metabolic features despite increased adiposity, and they may be allowed a period of grace for atherogenesis. Of course, metabolically healthy overweight/obese individuals may be needed to receive permanent medical follow-up because of increased risk of adverse long-term outcomes after all.[@b66-vhrm-13-001]

Gender difference in CAVI has been reported previously.[@b21-vhrm-13-001] Similarly, in this study, mean CAVI was higher in men (7.96 ± 1.14) than in women (7.69 ± 0.97), despite almost the same age in both groups (47.0 ± 13.0 in men and 47.1 ± 12.0 years in women). The mechanism of this gender difference in CAVI remains uncertain, although gender-related differences in body fat distribution may partly explain the phenomenon.

In 2002, brachial--ankle PWV (baPWV) was proposed to be a marker of vascular damage and was reported to be a predictive marker of CVD.[@b67-vhrm-13-001] Furthermore, baPWV correlates strongly with aortic (carotid--femoral) PWV, an established index of central arterial stiffness.[@b68-vhrm-13-001] However, PWV is known to depend on BP at the time of measurement. Therefore, the validity of PWV in reflecting actual arterial stiffness is controversial, and this parameter is unsuitable for evaluating the effect of antihypertensive drugs on the arterial wall. On the other hand, CAVI is independent of BP, which makes it more precise and reproducible than PWV as an index of arterial stiffness, whereas its predictive value of cardiovascular events has not been established adequately.[@b69-vhrm-13-001] Additionally, a multiple logistic analysis revealed that CAVI, but not baPWV, was associated with the presence of carotid and coronary arteriosclerosis.[@b29-vhrm-13-001]

The limitations of this study include the lack of data on some potential confounders such as proteinuria,[@b70-vhrm-13-001] alcohol consumption, menopause, and smoking status. In addition, the cross-sectional nature of this study does not allow determination of the time course for the development of vascular changes. Therefore, it was not possible to establish the exact pathophysiology linking BMI with CAVI. From these viewpoints, longitudinal cohort studies are needed to clarify the change in relationship between body composition and arterial stiffness during the development of cardiovascular risks.

Conclusion
==========

We demonstrated an inverse linear relationship between CAVI and BMI in healthy Japanese subjects, suggesting that systemic accumulation of adipose tissue per se may lead to a proportionate decrease in arterial stiffness in nonobese subjects and obese subjects without metabolic disorders.
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![Relationship between adjusted cardioankle vascular index and BMI in (**A**) male and (**B**) female subjects.\
**Notes:** CAVI was adjusted by age, sBP, and HDL-C. Data are presented as mean ± standard deviation. A significant linear trend \[*F* = 53.732, *P* \< 0.001 in (**A**) and *F* = 61.386, *P* \< 0.001 in (**B**)\] was observed for the whole BMI distribution.\
**Abbreviations:** BMI, body mass index; CAVI, cardioankle vascular index; sBP, systolic blood pressure; HDL-C, high-density lipoprotein-cholesterol.](vhrm-13-001Fig1){#f1-vhrm-13-001}

###### 

Characteristics of male and female participants

  Characteristics      All           Male          Female        *P* value[\*](#tfn2-vhrm-13-001){ref-type="table-fn"}
  -------------------- ------------- ------------- ------------- -------------------------------------------------------
  Number of subjects   23,257        12,729        10,528        --
  Age (years)          47.1 ± 12.5   47.0 ± 13.0   47.1 ± 12.0   0.692
  Height (cm)          163 ± 9       169 ± 6       156 ± 6       \<0.001
  Body weight (kg)     61.6 ± 12.2   68.4 ± 10.5   53.3 ± 8.4    \<0.001
  BMI (kg/m^2^)        22.9 ± 3.4    23.9 ± 3.2    21.7 ± 3.3    0.003
  CAVI                 7.84 ± 1.07   7.96 ± 1.14   7.69 ± 0.97   \<0.001
  sBP (mmHg)           124 ± 16      124 ± 16      123 ± 16      \<0.001
  dBP (mmHg)           76 ± 12       76 ± 12       75 ± 11       \<0.001
  γ-GTP (IU/L)         43 ± 56       43 ± 52       44 ± 60       0.415
  FPG (mg/dL)          91 ± 18       91 ± 18       91 ± 18       0.465
  HbA1c (NGSP, %)      5.3 ± 0.6     5.3 ± 0.6     5.3 ± 0.6     0.086
  TC (mg/dL)           209 ± 37      210 ± 37      208 ± 36      0.002
  TG (mg/dL)           113 ± 95      117 ± 100     108 ± 89      \<0.001
  HDL-C (mg/dL)        66 ± 19       65 ± 18       67 ± 19       \<0.001
  Non-HDL-C            144 ± 39      145 ± 39      142 ± 38      \<0.001
  Creatinine (mg/dL)   0.71 ± 0.15   0.80 ± 0.13   0.62 ± 0.10   0.055

**Notes:** Data are presented as mean ± standard deviation.

Student's *t*-test was used to compare male and female subjects.

**Abbreviations:** BMI, body mass index; CAVI, cardioankle vascular index; sBP, systolic blood pressure; dBP, diastolic blood pressure; γ-GTP, γ-glutamyl transpeptidase; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein-cholesterol.

###### 

Prevalence of major cardiovascular risk factors

  Variable                                    All (%)   Male (%)   Female (%)   *P* value[\*\*](#tfn4-vhrm-13-001){ref-type="table-fn"}
  ------------------------------------------- --------- ---------- ------------ ---------------------------------------------------------
  Older age (age ≥65; 1, \<65; 0)             9.2       9.2        6.6          \<0.001
  Obesity (BMI ≥25; 1, \<25; 0)               24.9      32.9       15.4         \<0.001
  Hypertension (BP ≥140/90; 1, \<140/90; 0)   15.3      16.1       14.3         \<0.001
  IFG (FPG ≥110; 1, \<110; 0)                 10.1      10.2       10.0         0.498
  Low HDL-C (HDL-C \<40; 1, ≥40; 0)           5.0       5.3        4.7          0.058

**Note:**

Fisher's exact test was used to compare male and female subjects.

**Abbreviations:** BMI, body mass index; BP, blood pressure; IFG, impaired fasting glucose; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein-cholesterol.

###### 

Correlation of cardioankle vascular index with clinical variables analyzed by multiple regression model

  Variable                      β coefficient   SE        *P* value
  ----------------------------- --------------- --------- -----------
  Gender (male; 1, female; 0)   0.149           0.125     \<0.001
  Age (years)                   0.584           0.017     \<0.001
  BMI (kg/m^2^)                 −0.119          0.003     \<0.001
  sBP (mmHg)                    0.139           17.105    \<0.001
  γ-GTP (IU/L)                  0.004           0.538     \<0.001
  HbA1c (%)                     −0.003          0.015     0.712
  HDL-C (mg/dL)                 −0.181          0.001     \<0.001
  Non HDL-C (mg/dL)             0.107           \<0.001   0.542
  Creatinine (mg/dL)            0.012           1.470     0.142

**Note:** Model: *r*^2^ = 0.598, *P* \< 0.001.

**Abbreviations:** SE, standard error; BMI, body mass index; sBP, systolic blood pressure; γ-GTP, γ-glutamyl transpeptidase; HbA1c, glycosylated hemoglobin; HDL-C, high-density lipoprotein-cholesterol.

###### 

Characteristics of male and female participants stratified by tertile of body mass index

  Variable                                                         Tertile of body mass index   *P* for trend                                  
  ---------------------------------------------------------------- ---------------------------- ------------------------- -------------------- ---------
  Male subjects                                                                                                                                
   Number of subjects                                              4,181                        4,365                     4,183                
   Age (years)                                                     45.2 ± 13.8                  48.4 ± 12.6               47.4 ± 12.3          \<0.001
   Height (cm)                                                     169 ± 6                      169 ± 6                   169 ± 6              \<0.001
   Body weight (kg)                                                59.2 ± 9.6                   67.6 ± 5.3                78.5 ± 9.4           \<0.001
   BMI (kg/m^2^)                                                   20.5 ± 1.3 (≤22.2)           23.6 ± 0.8 (22.3--24.9)   23.9 ± 3.2 (≥25.0)   \<0.001
   CAVI                                                            7.99 ± 1.13                  8.06 ± 1.12               7.84 ± 1.15          \<0.001
   Adjusted CAVI[\*\*\*](#tfn8-vhrm-13-001){ref-type="table-fn"}   8.16 ± 0.87                  7.97 ± 0.84               7.76 ± 0.87          \<0.001
   sBP (mmHg)                                                      123 ± 15                     127 ± 15                  131 ± 15             \<0.001
   dBP (mmHg)                                                      75 ± 11                      79 ± 11                   82 ± 11              \<0.001
   γ-GTP (IU/L)                                                    47 ± 68                      58 ± 69                   69 ± 66              \<0.001
   FPG (mg/dL)                                                     91 ± 18                      94 ± 21                   95 ± 22              \<0.001
   HbA1c (%)                                                       5.6 ± 0.6                    5.7 ± 0.7                 5.8 ± 0.8            \<0.001
   TC (mg/dL)                                                      197 ± 34                     209 ± 36                  214 ± 35             \<0.001
   TG (mg/dL)                                                      103 ± 79                     138 ± 109                 169 ± 135            \<0.001
   HDL-C (mg/dL)                                                   65 ± 17                      58 ± 15                   53 ± 13              \<0.001
   Non HDL-C (mg/dL)                                               132 ± 35                     151 ± 37                  162 ± 36             \<0.001
   Creatinine (mg/dL)                                              0.79 ± 0.11                  0.82 ± 0.29               0.82 ± 0.13          \<0.001
  Female subjects                                                                                                                              
   Number of subjects                                              3,585                        3,462                     3,481                
   Age (years)                                                     43.1 ± 12.0                  47.4 ± 11.4               50.9 ± 11.2          \<0.001
   Height (cm)                                                     157.7 ± 5.4                  156.4 ± 5.5               155.3 ± 5.6          \<0.001
   Body weight (kg)                                                46.5 ± 4.1                   52.1 ± 3.9                61.6 ± 7.9           \<0.001
   BMI (kg/m^2^)                                                   18.6 ± 1.1 (≤20.0)           21.2 ± 0.7 (20.1--22.5)   25.5 ± 2.7 (≥22.6)   \<0.001
   CAVI                                                            7.61 ± 0.94                  7.70 ± 0.96               7.76 ± 1.01          \<0.001
   Adjusted CAVI[\*\*\*](#tfn8-vhrm-13-001){ref-type="table-fn"}   7.89 ± 0.76                  7.70 ± 0.71               7.50 ± 0.76          \<0.001
   sBP (mmHg)                                                      114 ± 14                     119 ± 15                  127 ± 17             \<0.001
   dBP (mmHg)                                                      68 ± 10                      71 ± 10                   76 ± 11              \<0.001
   γ-GTP (IU/L)                                                    21 ± 18                      24 ± 25                   31 ± 29              \<0.001
   FPG (mg/dL)                                                     84 ± 8                       86 ± 9                    90 ± 16              \<0.001
   HbA1c (%)                                                       5.6 ± 0.4                    5.6 ± 0.5                 5.8 ± 0.6            \<0.001
   TC (mg/dL)                                                      202 ± 36                     212 ± 37                  226 ± 37             \<0.001
   TG (mg/dL)                                                      65 ± 34                      80 ± 52                   107 ± 63             \<0.001
   HDL-C (mg/dL)                                                   80 ± 18                      75 ± 17                   67 ± 16              \<0.001
   Non HDL-C (mg/dL)                                               122 ± 33                     137 ± 37                  156 ± 37             \<0.001
   Creatinine (mg/dL)                                              0.61 ± 0.14                  0.61 ± 0.08               0.61 ± 0.10          0.006

**Notes:**

CAVI was adjusted by age, sBP, and HDL-C. Data are presented as mean ± standard deviation, *P* value for trend by ANOVA.

**Abbreviations:** BMI, body mass index; CAVI, cardioankle vascular index; sBP, systolic blood pressure; dBP, diastolic blood pressure; γ-GTP, γ-glutamyl transpeptidase; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein-cholesterol; ANOVA, analysis of variance.

###### 

OR (95% CI) for high cardioankle vascular index (≥90th percentile)

  Variable                                 OR      95% CI         *P* value
  ---------------------------------------- ------- -------------- -----------
  Gender (male; 1, female; 0)              2.26    2.03--2.51     \<0.001
  Older age, years (age ≥65; 1, \<65; 0)   15.6    14.0--17.4     \<0.001
  Obesity (BMI ≥25; 1, \<25; 0)            0.804   0.720--0.899   \<0.001
  Hypertension (+; 1, -; 0)                2.28    2.06--2.54     \<0.001
  IFG (FPG ≥110; 1, \<110; 0)              1.17    1.01--1.37     0.0428
  Low HDL-C (HDL-C \<40; 1, ≥40; 0)        0.843   0.669--1.06    0.145

**Note:** Akaike's Information Criterion: 12,166, residual deviance: 12,152, *P* \< 0.0001.

**Abbreviations:** CI, confidence interval; BMI, body mass index; IFG, impaired fasting glucose; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein-cholesterol; OR, odds ratio.
